Aquestive Therapeutics
AQST
42 hedge funds and large institutions have $35M invested in Aquestive Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 20 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.9% less ownership
Funds ownership: 54.47% → 47.58% (-6.9%)
25% less funds holding
Funds holding: 56 → 42 (-14)
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
65% less capital invested
Capital invested by funds: $101M → $35M (-$66.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
+$2.08M |
| 2 |
Renaissance Technologies
New York
|
+$817K |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$665K |
| 4 |
JP Morgan Chase
New York
|
+$362K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.3M |
| 2 |
WCM
Wildcat Capital Management
New York
|
-$2.65M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.13M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$932K |
| 5 |
Two Sigma Investments
New York
|
-$835K |
AQST Hedge Fund Activity: Q1 2020 in Review
42 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2020, worth a combined $35M — down 65% from $101M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AQST and 7 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 20 added.
The largest buyer was DG Capital Management, opening a new position worth an estimated $2.08M. The largest seller was Opaleye Management, exiting entirely with an estimated $4.3M sold.
- 42 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2020, down from 56 in Q4 2019.
- Funds reported $35M of Aquestive Therapeutics stock for Q1 2020, down 65% quarter-over-quarter.
- 7 funds opened new Aquestive Therapeutics positions in Q1 2020 and 20 closed out, a net change of -13 holders.
- The largest Aquestive Therapeutics buyer in Q1 2020 was DG Capital Management, an estimated $2.08M added.
- The largest Aquestive Therapeutics seller in Q1 2020 was Opaleye Management, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2020.